Literature DB >> 19286880

Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Almudena Pérez-Rodríguez1, Aranzazu García-Rivero, Esther Lourés, Maria Fernanda López-Fernández, Angela Rodríguez-Trillo, Javier Batlle.   

Abstract

BACKGROUND: Mutation C1149R in the von Willebrand factor (VWF) gene has been thought to cause autosomal dominant severe type 1 von Willebrand disease (VWD). DESIGN AND METHODS: Eight patients from three unrelated families with this mutation were included in the present study who had distinct VWF abnormalities, not described in earlier studies.
RESULTS: The patients showed notably low levels of VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), VWF collagen binding (VWF:CB), and a reduced ristocetin-induced platelet aggregation (RIPA). VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratios were lower than 0.7. At basal conditions, all the VWF multimers were decreased in plasma, with a clearly lower relative proportion of the high molecular weight VWF multimers (HMWM). In high-resolution agarose gels, a large decrease in the relative proportions of the satellite bands was seen. The patients had a brief good response to desmopressin (DDAVP) administration, but the released VWF half-life was shorter than normal, indicating an accelerated clearance of their VWF. Platelet VWF was abnormal.
CONCLUSIONS: We conclude from the results obtained in these patients for plasma phenotypic data that this mutation should be classified as a VWD type 2A (IIE). DDAVP therapy may be somewhat helpful for this mutation, at least for mild to moderate bleeding. These data provide evidence that for VWD classification factors other than basal VWF, such as DDAVP response and platelet VWF, should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286880      PMCID: PMC2675680          DOI: 10.3324/haematol.2008.003301

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

2.  Type 2M von Willebrand disease: a variant of type 2A?

Authors:  J Batlle; A Pérez-Rodríguez; M D Franqueira; M F López-Fernández
Journal:  J Thromb Haemost       Date:  2007-11-23       Impact factor: 5.824

3.  Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis.

Authors:  A Yaël Nossent; Jeroen C J Eikenboom; Hans L Vos; Egbert Bakker; Bea C Tanis; Carine J M Doggen; Rogier M Bertina; Frits R Rosendaal
Journal:  Thromb Haemost       Date:  2006-06       Impact factor: 5.249

4.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

Review 5.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

6.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

7.  An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Authors:  Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

8.  Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

Authors:  Giancarlo Castaman; Stefan Lethagen; Augusto B Federici; Alberto Tosetto; Anne Goodeve; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Edith Fressinaud; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; John Pasi; Frank Hill; Ian Peake; Francesco Rodeghiero
Journal:  Blood       Date:  2008-01-29       Impact factor: 22.113

9.  Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).

Authors:  U Budde; R Schneppenheim; J Eikenboom; A Goodeve; K Will; E Drewke; G Castaman; F Rodeghiero; A B Federici; J Batlle; A Pérez; D Meyer; C Mazurier; J Goudemand; J Ingerslev; D Habart; Z Vorlova; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2008-03-01       Impact factor: 5.824

Review 10.  Type 1 von Willebrand disease.

Authors:  I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

View more
  5 in total

1.  Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Authors:  Augusto B Federici; Maria T Canciani
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

Review 2.  von Willebrand's disease diagnosis and laboratory issues.

Authors:  G Castaman; R R Montgomery; S S Meschengieser; S L Haberichter; A I Woods; M A Lazzari
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

3.  Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization.

Authors:  Marie-Daniéla Dubois; Ivan Peyron; Olivier-Nicolas Pierre-Louis; Serge Pierre-Louis; Johalène Rabout; Pierre Boisseau; Annika de Jong; Sophie Susen; Jenny Goudemand; Rémi Neviere; Pascal Fuseau; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Caterina Casari
Journal:  Res Pract Thromb Haemost       Date:  2022-06-15

4.  Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.

Authors:  Jing Dong; Xiaojuan Zhao; Sensen Shi; Zhenni Ma; Meng Liu; Qingyu Wu; Changgeng Ruan; Ningzheng Dong
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

5.  Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Authors:  Almudena Pérez-Rodríguez; Javier Batlle; Irene Corrales; Nina Borràs; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Nira Navarro; Carmen Altisent; Rocío Pérez-Montes; Shally Marcellini; Ana Moreto; Sonia Herrero; Inmaculada Soto; Nuria Fernández Mosteirín; Víctor Jiménez-Yuste; Nieves Alonso; Aurora de Andrés Jacob; Emilia Fontanes; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Nerea Castro Quismondo; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Maria Tenorio; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Manuela Dobón; Carlos Aguilar; Fernando Batlle; Francisco Vidal; María Fernanda López-Fernández
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.